MTIF offers microbiology services such as antiviral and antibacterial assays of solids, liquids, and porous materials as well as assessments of novel antimicrobial technologies. We offer standardised biofilm testing services, cytotoxicity and immunological assays, genomic analysis and also bespoke method development to fulfil the unique microbiology requirements of our customers.
Areas of Expertise
The Medical Technologies Innovation Facility´s portfolio fits with the special and unique antimicrobial assessments, consisting of standardised biofilm testing services , antiviral and antibacterial assays of solids, liquids, and porous materials as well as antimicrobial technologies with a subsequent cytotoxicity assay in order to investigate any impact of such materials on mammalian cells, in accordance to ASTM and ISO standards throughout the data collection, development and testing stage, from bench to bedside in a time-efficient manner.
Our research is also focused on synthesis and characterisation of materials and analysis of biofluids. Assessment of different materials is performed by a range of analytical techniques such as NMR, UV-Vis, FTIR and other spectroscopies, imaging, mechanical testing and investigation of leaching behaviour.
MTIF is happy to cover all levels of complexity within these dimensions and become part of the journey for customers who are discovering material functions.
Services To Rely On
In order to support your unique needs from bench to bedside and guide you throughout the all-encompassing microbiology procedures and practices, MTIF counts on experts such as Dr. Elena Hunter, a Research Fellow at MTIF at Nottingham Trent University. Dr.Hunter earned a B.Sc. in Biology and conducted research on hygrophilous dipterous insects’ behavioural ecology (Diptera, Empididae: Rhamphomyia, Hilara). In 2015, she completed an M.Sc. in Biotechnology from Nottingham Trent University.
On behalf of Pathoshield Ltd, MTIF undertook the study and evaluation of the effectiveness of a surface in reducing the infectivity of human coronavirus 229E (HCoV-229E). The antiviral effectiveness was analysed by tissue culture infectious dose 50 % test using MRC-5 human lung fibroblast cells.
The results of the study enabled Pathoshield Ltd to demonstrate proof of concept of their innovative surface treatment, and to go on to secure further investment for development.
The services provided by MTIF enabled us to obtain valuable proof of concept data and unlock further funding for development, we would definitely work with MTIF on further projects
Olivia Brown, Pathoshield
Biofilm Testing Services
Antiviral, Antimicrobial and Antibacterial Assays
Synthesis and Characterisation of Materials and Analysis of Biofluids
MICROBIOLOGY CONTACT FORM